Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Headlands Technologies LLC

Key Points

• Headlands Technologies LLC significantly reduced its stake by 59.9% in Agios Pharmaceuticals during the 1st quarter, now holding 10,715 shares valued at approximately $314,000.
• Analysts have recently downgraded Agios Pharmaceuticals, with Wall Street Zen changing their rating from "hold" to "sell", while the average target price for the stock is currently $56.33.
• Agios Pharmaceuticals reported worse-than-expected earnings for the last quarter, with a loss of $1.93 per share compared to analysts' estimates of a loss of $1.74.

Headlands Technologies LLC reduced its stake in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 59.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,715 shares of the biopharmaceutical company's stock after selling 16,021 shares during the period. Headlands Technologies LLC's holdings in Agios Pharmaceuticals were worth $314,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in AGIO. Jefferies Financial Group Inc. acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $49,290,000. Adage Capital Partners GP L.L.C. acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $9,957,000. Paradigm Biocapital Advisors LP acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $9,084,000. Deutsche Bank AG lifted its holdings in Agios Pharmaceuticals by 39.7% in the fourth quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock valued at $30,732,000 after acquiring an additional 265,637 shares during the last quarter. Finally, Casdin Capital LLC acquired a new position in Agios Pharmaceuticals in the fourth quarter valued at approximately $8,215,000.

Analyst Upgrades and Downgrades

AGIO has been the topic of a number of recent analyst reports. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Scotiabank decreased their price objective on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating on the stock in a report on Monday, July 28th. Finally, Bank of America decreased their price objective on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating on the stock in a report on Tuesday, July 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $56.33.

Agios Pharmaceuticals Stock Down 3.5%

NASDAQ:AGIO opened at $35.76 on Friday. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The stock's fifty day moving average is $36.24 and its two-hundred day moving average is $32.70. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of 3.25 and a beta of 0.80.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing analysts' consensus estimates of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%. The company had revenue of $12.50 million for the quarter, compared to analysts' expectations of $9.46 million. On average, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 18,700 shares of the stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $627,198.00. Following the transaction, the chief executive officer owned 105,401 shares of the company's stock, valued at $3,535,149.54. This represents a 15.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director David Scadden sold 1,400 shares of the stock in a transaction on Thursday, July 10th. The shares were sold at an average price of $40.00, for a total value of $56,000.00. Following the completion of the transaction, the director directly owned 17,603 shares in the company, valued at $704,120. This trade represents a 7.37% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 46,363 shares of company stock valued at $1,619,654. Insiders own 4.30% of the company's stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.